Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Annals of Neurology

• Publication date

  2011-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ana.22426PMID 21520239
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

  2010influential reference
• International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature

  2010cited by this paper
• FTY720 ameliorates MOG‐induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses

  2010cited by this paper
• Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients.

  2010cited by this paper
• T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis

  2010cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010influential reference
• Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

  2010cited by this paper
• Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

  2010influential reference
• Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors.

  2009cited by this paper
• Incomplete Inhibition of Sphingosine 1-Phosphate Lyase Modulates Immune System Function yet Prevents Early Lethality and Non-Lymphoid Lesions

  2009cited by this paper
• FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

  2009cited by this paper
• Treatment with immunosuppressants FTY720 and tacrolimus promotes functional recovery after spinal cord injury in rats.

  2009cited by this paper
• Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules

  2009cited by this paper
• Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.

  2008cited by this paper
• FTY720 modulates human oligodendrocyte progenitor process extension and survival

  2008cited by this paper
• Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod.

  2008cited by this paper
• FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

  2008cited by this paper
• Astrocytes in multiple sclerosis: A product of their environment

  2008cited by this paper
• Neuroprotection and neuroregeneration in multiple sclerosis

  2008cited by this paper
• Central nervous system-directed effects of FTY720 (fingolimod).

  2008cited by this paper
• Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease.

  2008cited by this paper
• Astrocytes—Friends or foes in multiple sclerosis?

  2007cited by this paper
• Oral‐intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects

  2007cited by this paper
• Sphingosine 1-phosphate regulates inflammation-related genes in human endothelial cells through S1P1 and S1P3.

  2007cited by this paper
• FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis.

  2007cited by this paper
• Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells

  2007cited by this paper
• The Immunomodulator FTY720 Has a Direct Cytoprotective Effect in Oligodendrocyte Progenitors

  2007cited by this paper
• Sphingosine-1-phosphate/sphingosine kinase pathway is involved in mouse airway hyperresponsiveness.

  2007cited by this paper
• Activation of sphingosine‐1‐phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration

  2007cited by this paper
• Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis

  2007influential reference
• Phosphorylated FTY720 promotes astrocyte migration through sphingosine‐1‐phosphate receptors

  2007cited by this paper
• FTY720 attenuates accumulation of EMAP-II+ and MHC-II+ monocytes in early lesions of rat traumatic brain injury

  2007cited by this paper
• Sphingosine-1-phosphate signaling in the cardiovascular system.

  2007cited by this paper
• Essential Roles of Sphingosine 1‐Phosphate/S1P1 Receptor Axis in the Migration of Neural Stem Cells Toward a Site of Spinal Cord Injury

  2007cited by this paper
• MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

  2007cited by this paper
• Immunosuppressive and Anti-angiogenic Sphingosine 1-Phosphate Receptor-1 Agonists Induce Ubiquitinylation and Proteasomal Degradation of the Receptor*

  2007cited by this paper
• Sphingosine 1-Phosphate Causes Airway Hyper-Reactivity by Rho-Mediated Myosin Phosphatase Inactivation

  2007cited by this paper
• Involvement of Sphingosine-1-Phosphate in Glutamate Secretion in Hippocampal Neurons

  2007cited by this paper
• FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1‐Year, Randomized Controlled Trial in Europe and Australasia

  2006cited by this paper
• Sphingosine‐1‐phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi‐protein‐coupled receptors

  2006cited by this paper
• Multiple sclerosis--the plaque and its pathogenesis.

  2006cited by this paper
• Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism

  2006cited by this paper
• Randomized Controlled Trial of FTY720 Versus MMF in De Novo Renal Transplantation

  2006cited by this paper
• Oral fingolimod (FTY720) for relapsing multiple sclerosis.

  2006cited by this paper
• Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.

  2006influential reference
• Pulmonary and vascular pharmacology of sphingosine 1-phosphate.

  2006cited by this paper
• FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.

  2006cited by this paper
• Physiologically Based Pharmacokinetic Modeling of FTY720 (2-Amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in Rats After Oral and Intravenous Doses

  2006cited by this paper
• Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.

  2006cited by this paper
• Remyelination is extensive in a subset of multiple sclerosis patients.

  2006cited by this paper
• FTY720: Placebo‐Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects

  2006cited by this paper
• Immunomodulator FTY720 Induces eNOS-Dependent Arterial Vasodilatation via the Lysophospholipid Receptor S1P3

  2005cited by this paper
• Lymphocyte Sequestration Through S1P Lyase Inhibition and Disruption of S1P Gradients

  2005cited by this paper
• Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways

  2005cited by this paper
• Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit

  2005cited by this paper
• FTY720, a Novel Immunomodulator in de Novo Kidney Transplant Patients: Pharmacokinetics and Exposure‐Response Relationship

  2005cited by this paper
• FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.

  2005cited by this paper
• Sphingosine Kinase 2 Is Required for Modulation of Lymphocyte Traffic by FTY720*

  2005cited by this paper
• Novel role of sphingosine kinase 1 as a mediator of neurotrophin‐3 action in oligodendrocyte progenitors

  2005cited by this paper
• Essential Role for Sphingosine Kinases in Neural and Vascular Development

  2005cited by this paper
• Sphingosine-1-Phosphate Agonists Increase Macrophage Homing, Lymphocyte Contacts, and Endothelial Junctional Complex Formation in Murine Lymph Nodes

  2005cited by this paper
• Extracellular release of newly synthesized sphingosine‐1‐phosphate by cerebellar granule cells and astrocytes

  2005cited by this paper
• Edg8/S1P5: An Oligodendroglial Receptor with Dual Function on Process Retraction and Cell Survival

  2005cited by this paper
• Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

  2005cited by this paper
• Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network

  2005cited by this paper
• Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a

  2005cited by this paper
• FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation

  2005cited by this paper
• The Heart Rate Decrease Caused by Acute FTY720 Administration Is Mediated by the G Protein‐Gated Potassium Channel IKACh

  2005cited by this paper
• Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

  2004cited by this paper
• Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

  2004cited by this paper
• The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors

  2004cited by this paper
• Mice Deficient in Sphingosine Kinase 1 Are Rendered Lymphopenic by FTY720*

  2004cited by this paper
• Sphingosine‐1‐phosphate induces proliferation and morphological changes of neural progenitor cells

  2004cited by this paper
• FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors.

  2004cited by this paper
• Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.

  2004influential reference
• Multiple‐Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects

  2004cited by this paper
• Generation and metabolism of bioactive sphingosine‐1‐phosphate

  2004cited by this paper
• Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes

  2004cited by this paper
• Growth factor pre‐treatment differentially regulates phosphoinositide turnover downstream of lysophospholipid receptor and metabotropic glutamate receptors in cultured rat cerebrocortical astrocytes

  2004cited by this paper
• Endothelial cell barrier regulation by sphingosine 1‐phosphate

  2004cited by this paper
• Central memory and effector memory T cell subsets: function, generation, and maintenance.

  2004cited by this paper
• Lysophospholipid receptors: signaling and biology.

  2004cited by this paper
• Constitutive expression of the S1P1 receptor in adult tissues.

  2004cited by this paper
• FTY720: Sphingosine 1‐Phosphate Receptor‐1 in the Control of Lymphocyte Egress and Endothelial Barrier Function

  2004cited by this paper
• Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate*

  2004cited by this paper
• Characterization of lysophosphatidic acid and sphingosine‐1‐phosphate‐mediated signal transduction in rat cortical oligodendrocytes

  2004cited by this paper
• S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate.

  2003cited by this paper
• Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes.

  2003cited by this paper
• Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS.

  2003cited by this paper
• Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases*

  2003influential reference
• Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes.

  2003cited by this paper
• Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study

  2003cited by this paper
• Signaling and biological actions of sphingosine 1-phosphate.

  2003cited by this paper
• Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients

  2003cited by this paper
• Sphingosine-1-phosphate: an enigmatic signalling lipid

  2003cited by this paper
• The roles of ceramide and complex sphingolipids in neuronal cell function.

  2003cited by this paper
• Sphingosine-1-Phosphate Receptor Agonism Impairs the Efficiency of the Local Immune Response by Altering Trafficking of Naive and Antigen-Activated CD4+ T Cells

  2003cited by this paper
• Linking Chinese medicine and G-protein-coupled receptors.

  2003cited by this paper
• Assessment of the role of sphingosine 1-phosphate and its receptors in high-density lipoprotein-induced stimulation of astroglial cell function.

  2003cited by this paper
• The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2

  2003cited by this paper

• Targeted Drug Delivery in Animal Models of Demyelination: The Role of Plant-Based Nanoparticles with a Focus on Multiple Sclerosis

  2026cites this paper
• Developments in pharmacotherapy for the preservation of ovarian function during cancer treatment

  2025cites this paper
• Fingolimod Exerts Therapeutic Effects on Autistic Mice via Improving the Structure and Function of Meningeal Lymphatics

  2025cites this paper
• Clinical Status and CNS Adverse Drug Report of Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis.

  2025cites this paper
• S1PR1-biased activation drives the resolution of endothelial dysfunction-associated inflammatory diseases by maintaining endothelial integrity

  2025cites this paper
• T cell receptor activation contributes to brain damage after intracerebral hemorrhage in mice

  2025cites this paper
• [An autopsy case of primary progressive multiple sclerosis with minimal acute inflammation and remyelination over an 11-year course].

  2025cites this paper
• The Role of Brain-Derived Neurotrophic Factor as an Essential Mediator in Neuronal Functions and the Therapeutic Potential of Its Mimetics for Neuroprotection in Neurologic and Psychiatric Disorders

  2025cites this paper
• Acupoint catgut embedding alleviates experimental autoimmune encephalomyelitis by modulating neuroinflammation and potentially inhibiting glia activation through JNK and ERK pathways

  2025cites this paper
• Clinical outcomes after switching from fingolimod to B-cell-depleting therapies in multiple sclerosis: systematic review and meta-analysis

  2025cites this paper
• New approach of using medicinal mushrooms for managing and curing multiple sclerosis.

  2025cites this paper
• Development of Seborrheic Keratosis and Human Papillomavirus (HPV) Infection Following Four Months of Fingolimod Treatment in a Patient With Multiple Sclerosis: A Report of a Rare Case

  2025influential citation
• Sphingosine-1-Phosphate Modulation in Neurological Disorders: Insights from MS and Stroke

  2025cites this paper
• Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer

  2024cites this paper
• Exploring the molecular targets of fingolimod and siponimod for treating the impaired cognition of schizophrenia using network pharmacology and molecular docking

  2024cites this paper
• Sex-Dependent Efficacy of Sphingosine-1-Phosphate Receptor Agonist FTY720 in Mitigating Huntington's Disease.

  2024cites this paper
• Mannose-Integrated Nanoparticle Hitchhike Glucose Transporter 1 Recycling to Overcome Various Barriers of Oral Delivery for Alzheimer's Disease Therapy.

  2024cites this paper
• Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis.

  2024cites this paper
• Neutrophil Membrane‐Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapy

  2024cites this paper
• Role of Regulatory T Cells in Intracerebral Hemorrhage

  2024cites this paper
• Prebiotic inulin controls Th17 cells mediated central nervous system autoimmunity through modulating the gut microbiota and short chain fatty acids

  2024cites this paper
• Profiling of B cells and their subsets by whole blood gene expression analysis versus flow cytometry in multiple sclerosis.

  2024cites this paper
• Mapping the Therapeutic Options for Multiple Sclerosis in Brazil: A Comprehensive Analysis

  2024cites this paper
• Drug-induced retinal vein occlusion: a disproportionality analysis from the FDA adverse event reporting system (2004–2023)

  2024cites this paper
• Impact of Fingolimod Discontinuation Strategy on Recurrence of Disease Activity in Individuals With Multiple Sclerosis.

  2024cites this paper
• Effects of disease-modifying therapies on lipid parameters in patients with multiple sclerosis.

  2023cites this paper
• Neurovascular Inflammation and Complications of Thrombolysis Therapy in Stroke

  2023cites this paper
• An update on combination therapies for multiple sclerosis: where are we now?

  2023cites this paper
• FTY720 attenuates acute colitis via colonic T cells reduction and inhibition of M1 macrophages polarization independent of CCR2-mediated monocytes input.

  2023cites this paper
• T-cell infiltration in the central nervous system and their association with brain calcification in Slc20a2-deficient mice

  2023cites this paper
• Investigation of Biochemical Factors in Multiple Sclerosis Patients With Fingolimod and Natalizumab Drugs

  2023cites this paper
• A Theranostic Small-Molecule Prodrug Conjugate for Neuroendocrine Prostate Cancer

  2023cites this paper
• 2-Aminobenzoxazole Derivatives as Potent Inhibitors of the Sphingosine-1-Phosphate Transporter Spinster Homolog 2 (Spns2).

  2023cites this paper
• The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis

  2023influential citation
• Lysophospholipid (S1P) receptors in GtoPdb v.2023.1

  2023cites this paper
• The Development of Drug Delivery Systems for Efficient Intracranial Hemorrhage Therapy

  2023cites this paper
• The mechanism of microglia-mediated immune inflammation in ischemic stroke and the role of natural botanical components in regulating microglia: A review

  2023cites this paper
• Synthesis and Comprehensive in Vivo Activity Profiling of Olean-12-en-28-ol, 3β-Pentacosanoate in Experimental Autoimmune Encephalomyelitis: A Natural Remyelinating and Anti-Inflammatory Agent

  2023cites this paper
• Lymphocyte-Related Immunomodulatory Therapy with Siponimod (BAF-312) Improves Outcomes in Mice with Acute Intracerebral Hemorrhage

  2023cites this paper
• Sphingosine 1-phosphate signaling during infection and immunity.

  2023cites this paper
• The efficacy and safety of fingolimod plus standardized treatment versus standardized treatment alone for acute ischemic stroke: A systematic review and meta‐analysis

  2022cites this paper
• The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary

  2022cites this paper
• Targeted Delivery Platforms for the Treatment of Multiple Sclerosis.

  2022cites this paper
• The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination

  2022cites this paper
• CNS border-associated macrophages in the homeostatic and ischaemic brain.

  2022cites this paper
• Vaccination and immunotherapies in neuroimmunological diseases

  2022cites this paper
• Intranasal administration of fingolimod (FTY720) attenuates demyelination area in lysolecithin-induced demyelination model of rat optic chiasm.

  2022cites this paper
• FTY720 requires vitamin B12-TCN2-CD320 signaling in astrocytes to reduce disease in an animal model of multiple sclerosis

  2022cites this paper
• S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review

  2022cites this paper
• Single-Nucleus RNA-seq of Normal-Appearing Brain Regions in Relapsing-Remitting vs. Secondary Progressive Multiple Sclerosis: Implications for the Efficacy of Fingolimod

  2022cites this paper
• Neuroprotective approach in acute ischemic stroke: A systematic review of clinical and experimental studies

  2022cites this paper
• The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis

  2022cites this paper
• Mediastinal abscess and osteomyelitis as side effects of immunomodulatory treatment with fingolimod

  2022cites this paper
• Ponesimod inhibits astrocyte‐mediated neuroinflammation and protects against cingulum demyelination via S1P1‐selective modulation

  2022cites this paper
• Neuroprotection by Ozanimod Following Intracerebral Hemorrhage in Mice

  2022cites this paper
• Interleukin-31 and soluble CD40L: new candidate serum biomarkers that predict therapeutic response in multiple sclerosis

  2022cites this paper
• Are different degrees of lymphopenia for FTY720 associated with serious infectious-type events? No

  2022cites this paper
• Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease

  2022cites this paper
• Lysophospholipid (S1P) receptors in GtoPdb v.2021.2

  2021cites this paper
• G-protein-coupled receptor P2Y10 facilitates chemokine-induced CD4 T cell migration through autocrine/paracrine mediators

  2021cites this paper
• Macrophage‐Disguised Manganese Dioxide Nanoparticles for Neuroprotection by Reducing Oxidative Stress and Modulating Inflammatory Microenvironment in Acute Ischemic Stroke

  2021cites this paper
• Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)

  2021cites this paper
• Ponesimod protects against neuronal death by suppressing the activation of A1 astrocytes in early brain injury after experimental subarachnoid hemorrhage

  2021influential citation
• A2B Adenosine Receptors and Sphingosine 1-Phosphate Signaling Cross-Talk in Oligodendrogliogenesis

  2021cites this paper
• Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2

  2021cites this paper
• Selective Sphingosine-1-Phosphate Receptor 1 Modulation Ameliorates TBI-induced Neurological Deficit after CCI.

  2021cites this paper
• Wielding the Double‐Edged Sword of Inflammation: Building Biomaterial‐Based Strategies for Immunomodulation in Ischemic Stroke Treatment

  2021cites this paper
• An update on the pharmacological management and prevention of cerebral edema: current therapeutic strategies

  2021cites this paper
• Ozanimod for relapsing-remitting multiple sclerosis

  2021cites this paper
• Targeting Acute Inflammation

  2021cites this paper
• Oxidative stress activity of fingolimod in multiple sclerosis.

  2021cites this paper
• FTY720 Reduces Endothelial Cell Apoptosis and Remodels Neurovascular Unit after Experimental Traumatic Brain Injury

  2021cites this paper
• Tertiary lymphoid organs are associated with the progression of kidney damage and regulated by interleukin-17A

  2021cites this paper
• Critical Roles of Lysophospholipid Receptors in Activation of Neuroglia and Their Neuroinflammatory Responses

  2021cites this paper
• Treating MS After 50: the Role of Age in Therapeutic Decision-Making

  2021cites this paper
• Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation and Prevent Parkinson’s Disease Symptoms in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model

  2020cites this paper
• S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer.

  2020cites this paper
• Biocompatible Chemotherapy for Leukemia by Acid-Cleavable, PEGylated FTY720.

  2020cites this paper
• Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets

  2020influential citation
• Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia

  2020cites this paper
• N2 year in review

  2020cites this paper
• Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies.

  2020cites this paper
• Drug Induced Maculopathies

  2020cites this paper
• Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications

  2020cites this paper
• Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis

  2020cites this paper
• The Effect of Fingolimod (FTY720) Treatment on Liver Enzyme Levels in Relapsing-Remitting Multiple Sclerosis Patients

  2020influential citation
• Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects

  2020cites this paper
• Emerging Therapies for the Treatment of Multiple Sclerosis

  2020cites this paper
• The Role of TH17 Cells in Multiple Sclerosis: Therapeutic Implications.

  2020cites this paper
• Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process

  2020cites this paper
• Correlation between IL-31 and sCD40L plasma levels in Fingolimod-treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS).

  2020cites this paper
• Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and TH17 responses

  2020cites this paper
• An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-β1 and fingolimod therapy.

  2020cites this paper
• Communications Between Peripheral and the Brain-Resident Immune System in Neuronal Regeneration After Stroke

  2020cites this paper
• Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models.

  2020cites this paper
• Unlabeled lysophosphatidic acid receptor binding in free solution as determined by a compensated interferometric reader

  2020cites this paper
• Multimodal MRI Response to Fingolimod in Multiple Sclerosis: A Nonrandomized, Single Arm, Observational Study

  2020cites this paper
• Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study

  2020cites this paper
• Safety of Newer Disease Modifying Therapies in Multiple Sclerosis

  2020cites this paper
• The Rationale for Potential Pharmacotherapy of COVID-19

  2020cites this paper